** Shares of drug developer Adaptimmune Therapeutics
rise ~3% to 81 cents
** Co says its cell therapy being developed to treat two rare types of cancers met the main goal of a mid-stage study
** The therapy, lete-cel, helped 42% of study patients achieve partial or complete response to the treatment - ADAP
** Co plans to begin application process for lete-cel in 2025 for the treatment of both synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) - ADAP
** Synovial sarcoma is a cancer in the soft tissues that most often affects young people and MRCLS is a cancer that grows in the cells that store fat in the body
** Including session gains, stock up ~2% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.